


Prenatal Genetic Screening (IPS/SIPS/QUAD) is not indicated for predicting obstetrical outcomes. However, for women who have had screening for Down syndrome and are found to have an abnormal serum analyte the following risks and recommendations apply:

Probability of an Adverse Obstetrical Outcome from the Analysis of Maternal Serum Markers

		Cut off Value (MoM)	Adverse Obstetrical Outcome (stillbirth, preterm birth <34 weeks, HELLP syndrome)	Pre-Eclampsia
Population Risk (or Pre-Test Probability)			2 %	4.8%
Low	PAPP – A	≤0.15	9%	11%
Low	uE3	≤0.40	8%	6%
		≤0.30	4%	N/A
High	AFP	≥2.5	11%	11%
		≥3.0	17%	14%
		≥3.5	18%	18%
High	hCG	≥4.0	10%	15%
		≥4.5	18%	22%
High	Inhibin A	≥3.0	11%	17%
		≥3.5	14%	22%
		≥4.0	20%	25%
		≥4.5	25%	29%

Recommended Management

Pregnancies with abnormal serum analyte(s) AND a negative screen or positive screen for T21 or T18, with negative results on NIPT or Amnio, should be followed as below:



Related References:

Gagnon, A et al. Obstetrical Complications Associated with Abnormal Maternal Serum Marker Analytes. J Obstet Gynaecol Can. 2008 Oct; 30(10):918-49.
Dugoff L; Society for Maternal-Fetal Medicine. First-and Second-Trimester Maternal Serum Markers for Aneuploidy and Adverse Obstetrical Outcomes. 2010 May; 115(5):1052-61.